I MAB Stock Quote IMAB - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.685

Bid

1.68

Ask

1.69

Volume

120,588

1.67 Day's Range 1.775

0.00 52 Week Range 0.00

Market Cap

Previous Close

1.77

Open

1.76

Last Trade

1.69

Last Trade Time

12:59:04

Financial Volume

$ 207,508

VWAP

1.7208

Average Volume (3m)

Shares Outstanding

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.i-mabbiopharma.com

Headquarters

Grand Cayman, Cym

Founded

1970

I MAB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMAB. The last closing price for I MAB was $1.77. Over the last year, I MAB shares have traded in a share price range of $ 0.00 to $ 0.00.

I MAB currently has 0 shares outstanding.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md., June 6, 2024 ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire ROCKVILLE, Md., June 5, 2024...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GRDIGRIID Infrastructure Inc	$ 1.2801 (128.59%)	110.11M
ZAPPZapp Electric Vehicles Group Ltd	$ 3.03 (122.79%)	71.88M
MGOLMGO Global Inc	$ 0.81 (76.70%)	144.76M
RELIReliance Global Group Inc	$ 0.635 (62.36%)	107.64M
NNENano Nuclear Energy Inc	$ 16.3078 (40.58%)	3.09M
WHLRWheeler Real Estate Investment Trust Inc	$ 2.72 (-82.70%)	119.99k
KAVLKaival Brands Innovations Group Inc	$ 2.955 (-34.33%)	844.59k
MBIOMustang Bio Inc	$ 0.562 (-33.89%)	32.83M
TRVNTrevena Inc	$ 0.25 (-29.46%)	36.33M
NLSPNLS Pharmaceutics Ltd	$ 0.1934 (-28.40%)	12.32M
NVDANVIDIA Corporation	$ 133.46 (-1.56%)	290.45M
SMXSMX Security Matters Public Company	$ 0.1628 (36.81%)	161.06M
NKLANikola Corporation	$ 0.35945 (-25.25%)	160.14M
MGOLMGO Global Inc	$ 0.81 (76.70%)	144.76M
GRDIGRIID Infrastructure Inc	$ 1.285 (129.46%)	110.11M